Close Menu

NEW YORK – Agendia said today that it has partnered with PathoNext to offer its MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping tests in Germany.

As part of the agreement, PathoNext will run the tests in its own labs using next-generation sequencing (NGS) and partner with HiSS, Agendia's distributor in Germany, to offer the tests to German patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.